Clinical trials: Priming
Misoprostol Allergy
Misoprostol for Cervical Priming Before Office Hysteroscopy
The objective of the present study is to evaluate the appropriate route of administration of misoprostol, either oral or vaginal, for cervical priming to facilitate the procedure of office hysteroscopy and reduce patient…
- Trial name
- NCT03276000
- Testing
- office hysteroscopy
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Kasr El Aini Hospital
Influenza
H5N1 Priming and Boosting Strategies
Severe disease in humans due to bird influenza viruses (H5N1) has led to concern that this virus may result in a widespread outbreak of bird flu.
- Trial name
- NCT00703053
- Testing
- A/Vietnam/1203/04, A/Indonesia/05/05
- Where
- 5 sites in United States
- Volunteers
- 505 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Meningitis
A Phase 3 Study to Assess the Immune Response And Safety Of Rmenb+Omv Nz In Primed Healthy Participants (10 To 20 Years Old)
The main purpose of this study is to evaluate the immune response and safety of a booster dose of the meningococcal group B vaccine, rMenB+OMV NZ (also known as Bexsero), in adolescents and young adults aged 10 to 20 years.
- Trial name
- NCT06995430
- Testing
- rMenB+OMV NZ vaccine
- Where
- 17 sites in Finland, Italy and 2 more
- Volunteers
- 312 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Multiple Myeloma, Neoplasm, Plasma Cell
a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease
This is a single arm study to evaluate the efficacy and safety of BCMA-targeted prime CAR-T cells therapy for patients with relapsed/refractory Multiple Myeloma.
- Conditions
- Multiple Myeloma, Neoplasm, Plasma Cell, Multiple Myeloma in Relapse
- Trial name
- NCT04776330
- Testing
- BCMA targeted prime CAR-T cells
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Influenza
H7N9 Boost in Healthy Adults
The study will be an open-label phase 2 clinical trial of a single dose of an inactivated H7N9 influenza vaccine (non-adjuvanted).
- Trial name
- NCT02586792
- Testing
- Monovalent influenza A/H7N9 virus vaccine
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Neuroendocrine Tumor of Pancreas, Multiple Endocrine Neoplasia Type 1
Precision Radiotherapy Using MR-linac for Pancreatic Neuroendocrine Tumours in MEN1 Patients
Patients with the Multiple Endocrine Neoplasia type 1 (MEN1) syndrome are genetically predisposed for developping multiple pancreatic neuro-endocrine tumours (pNET).
- Trial name
- PRIME (NCT05037461)
- Testing
- High-dose-high precision MR-guided radiotherapy
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- J.M. de Laat
Myelodysplastic Syndromes
Clofarabine, Cytarabine, and G-CSF in Treating Patients With Myelodysplastic Syndromes
RATIONALE: Drugs used in chemotherapy, such as clofarabine and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00503880
- Testing
- filgrastim, clofarabine, cytarabine
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Nebraska
Acute Kidney Injury
Prediction and Management of Acute Kidney Injury With Explainable Artificial Intelligence
The goal of this clinical trial is to compare the occurrence of acute kidney injury (AKI) in inpatients when information from the 'PRIME solution' (AKI prediction program utilizing artificial intelligence) is provided.
- Trial name
- PRIME (NCT05937451)
- Testing
- PRIME solution
- Where
- South Korea
- Volunteers
- 1,438 people
- Sponsor
- Seoul National University Hospital
Avian Influenza
Evaluation of Priming Effects by PLAI Vaccine on the Subsequent Response to Inactivated H5N1 Vaccine
This study aim to compare immunogenicity of the inactivated H5 influenza vaccine single dose between subjects previously vaccinated with LAIV H5N2 and naïve subjects
- Trial name
- NCT02229357
- Testing
- OrniFlu® inactivated vaccine
- Where
- Thailand
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Mahidol University
Extramedullary Disease in Multiple Myeloma, Multiple Myeloma
External Beam Radiation Therapy in Combination With Talquetamab for the Treatment of Multiple Myeloma Patients With Extramedullary Disease
This phase I/II trial tests the safety and effectiveness of extramedullary disease (EMD)-directed external beam radiation therapy (EBRT) in combination with talquetamab for the treatment of multiple myeloma patients with…
- Trial name
- NCT06572605
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- City of Hope Medical Center
Influenza
H9 Priming Study in Healthy Adults
The purpose of this research study is to determine whether prior exposure to A/H2N2 viruses is associated with better antibody (part of the immune system that fights infection) responses after vaccination with an A/H9N2 flu…
- Trial name
- NCT00617331
- Testing
- Subvirion inactivated influenza A/H9N2 (G9 variant) vaccine
- Where
- United States
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Type 2 Diabetes, Coronary Heart Disease
Trial on Safety & Performance of TAXUS Element vs. XIENCE Prime Stent in Treatment of Coronary Lesion in Diabetics
The TUXEDO-India is a prospective, single blind, multi-center randomized clinical trial to assess the TAXUS Element™ in a consecutive population of diabetic patients with coronary artery disease undergoing coronary…
- Trial name
- Tuxedo (NCT03125772)
- Testing
- TAXUS Element™ Paclitaxel-Eluting Stent System, Xience PRIME Everolimus-Eluting Stent System
- Where
- India
- Volunteers
- 1,830 people
- Sponsor
- Fortis Escorts Heart Institute
HIV Infections
Evaluating the Safety and Priming Response of an HIV Vaccine Regimen in Healthy, HIV-Uninfected Adults
This study will evaluate the safety of and the body's immune response to experimental HIV vaccine regimens using different vaccine priming combination, and boosting with the vaccines NYVAC and AIDSVAX® B/E.
- Trial name
- NCT01799954
- Testing
- DNA-HIV-PT123, NYVAC-HIV-PT1, NYVAC-HIV-PT4
- Where
- Switzerland
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- HIV Vaccine Trials Network
HIV Infections
A Study of LIPO-5 and ALVAC-HIV (vCP1452) as Possible HIV Vaccines
This study will test the immune system response to and safety of two HIV vaccines alone and in combination: ALVAC-HIV (vCP1452) and LIPO-5. ALVAC-HIV (vCP1452) uses a canarypox virus with man-made parts of HIV attached to it.
- Trial name
- NCT00076063
- Testing
- ALVAC-HIV (vCP1452), LIPO-5
- Where
- 11 sites in United States
- Volunteers
- 174 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
PPOS, GnRH Antagonist
PPOS Protocol Versus GnRH Anatagonist for Expected Normal Responder Patients Undergoing ART : a Randomized Clinical Trial
The aim of this study is to compare the efficacy and safety of Progestin-Primed Ovarian Stimulation (PPOS) protocol versus the fixed GnRH antagonist protocol in expected normal responder patients undergoing intracytoplasmic sperm…
- Conditions
- PPOS, GnRH Antagonist, Assisted Reproductive Techniques
- Trial name
- PPOS vs GnRH (NCT06868576)
- Testing
- Dydrogesterone Oral Tablet, Cetrorelix (Cetrotide)
- Where
- Egypt
- Volunteers
- 328 people
- Sponsor
- Kasr El Aini Hospital
Covid19 Vaccine
A Heterologous Prime-boost Study to Evaluate Immunogenicity and Safety of mRNA-1273 With MVC-COV1901 in Adults
The primary objective of the study is to evaluable the safety and to demonstrate the immunogenicity of heterologous prime-boost (mRNA-1273, MVC-COV1901), compared to homologous prime-boost (mRNA-1273), with an interval of 8-12…
- Trial name
- NCT05079633
- Testing
- Homologous boost schedule, Heterologous boost schedule
- Where
- Taiwan
- Volunteers
- 220 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
HIV Infections
Study to Compare the Immunogenicity and Safety of Two HIV Preventive Vaccinations in Healthy Volunteers
The purpose of the trial is to evaluate the effect upon immune system of two regimens of preventive HIV vaccination in healthy adult volunteers.
- Trial name
- EV03/ANRSVAC20 (NCT00490074)
- Testing
- DNA-C, NYVAC-C
- Where
- 2 sites in France, Switzerland
- Volunteers
- 147 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
Blood Transfusion Associated Adverse Reactions
Antihistamine for Prevention of HTR After Blood Primed CPB
This study will be a randomized, double-blinded, placebo-controlled study conducted at a university hospital. Forty children undergoing elective repair of a congenital heart defect will be included.
- Trial name
- HTR - CPB (NCT07536152)
- Testing
- Antihestamine
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Kasr El Aini Hospital
Prophylaxis of Avian Influenza Vaccine
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Adults Unprimed and Primed With Adjuvanted or Non-adjuvanted Influenza Vaccines
Valuate the immune response and reactogenicity of H5N1 vaccination in a primed population (H5N3 adjuvanted or non-adjuvanted vaccine) compared to immunologically naïve subjects
- Trial name
- NCT00478816
- Testing
- Fluad H5N1 Pandemic Influenza Vaccine
- Where
- United Kingdom
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Chronic Granulomatous Disease, Granulomatous Disease, Chronic
A Study of the Safety and Efficacy of Prime Editing (PM359) in Participants With p47phox Autosomal Recessive Chronic Granulomatous Disease (CGD )
This is an open-label, single-arm, multicenter Phase 1/2 study evaluating the safety and efficacy of gene therapy by transplantation of Prime Edited autologous CD34+ stem cells modified ex vivo (PM359) in participants with…
- Trial name
- NCT06559176
- Testing
- PM359
- Where
- 5 sites in United States, Canada and 1 more
- Volunteers
- 12 people
- Sponsor
- Prime Medicine, Inc.